title: A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy.
authors.affiliation: Urologic Oncology Branch, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Lattouf
authors.forename: Philip M
authors.initials: PM
authors.lastname: Arlen
authors.forename: Peter A
authors.initials: PA
authors.lastname: Pinto
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage*; D017321:Clinical Trials, Phase I as Topic; D005240:Feasibility Studies; D005587:Fowlpox virus; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000008:administration & dosage*; D014616:Vaccinia virus
chemical_list: D019496:Cancer Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C479602:rF-TRICOM vaccine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor